drugset / Trial / NCT00777673
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Phase 2
Unknown
60 enrolled
University of Tennessee Cancer Institute
Celgene Corporation · collabGenentech, Inc. · collabNational Comprehensive Cancer Network · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine how well this combination of chemotherapy drugs works with bevacizumab in eliminating primary tumor in the breast prior to surgery(pathological complete response or pCR in the breast). Bevacizumab is a drug that works by blocking new blood vessel formation by the tumor cells. Giving chemotherapy and bevacizumab before surgery may allow for lesser amount of breast tissue to be removed. To be able to predict in the future which patients are more likely to get pCR to this drug combination, specialized tests on tumor tissue will be performed.
Timeline
- Start
- 2008-10
- Primary completion
- 2013-01
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | — | Intravenous |
| Background | Pegfilgrastim | Protein / enzyme biologic | — | — |